Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

In response to COVID-19 pandemic, we have launched a vaccine development program against SARS-CoV-2. Here we report the safety, tolerability, and immunogenicity of a recombinant protein RBD fusion heterodimeric vaccine against SARS-CoV-2 (PHH-1V) evaluated in a phase 1-2a dose-escalation, randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Leal, Lorna, Pich, Judit, Ferrer, Laura, Nava, Jocelyn, Martí-Lluch, Ruth, Esteban, Ignasi, Pradenas, Edwards, Raïch-Regué, Dàlia, Prenafeta, Antoni, Escobar, Karla, Pastor, Carmen, Ribas-Aulinas, Marc, Trinitè, Benjamin, Muñoz-Basagoiti, Jordana, Domenech, Gemma, Clotet, Bonaventura, Corominas, Júlia, Corpes-Comes, Aida, Garriga, Carme, Barreiro, Antonio, Izquierdo-Useros, Nuria, Arnaiz, Joan Albert, Soriano, Alex, Ríos, José, Nadal, Marga, Plana, Montserrat, Blanco, Julià, Prat, Teresa, Torroella, Elia, Ramos, Rafel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541407/
https://www.ncbi.nlm.nih.gov/pubmed/37775521
http://dx.doi.org/10.1038/s41541-023-00736-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541407/
https://www.ncbi.nlm.nih.gov/pubmed/37775521
http://dx.doi.org/10.1038/s41541-023-00736-5

Ejemplares similares